Loading...

We've got a brand new version of Simply Wall St! Try it out

Opthea

ASX:OPT
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OPT
ASX
A$721M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The last earnings update was 102 days ago. More info.


Add to Portfolio Compare Print
  • Opthea has significant price volatility in the past 3 months.
OPT Share Price and Events
7 Day Returns
-3.7%
ASX:OPT
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
408.8%
ASX:OPT
50.9%
AU Biotechs
16.3%
AU Market
OPT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Opthea (OPT) -3.7% -19% 5.5% 408.8% 302.8% 1712.5%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • OPT outperformed the Biotechs industry which returned 50.9% over the past year.
  • OPT outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
OPT
Industry
5yr Volatility vs Market

Value

 Is Opthea undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Opthea. This is due to cash flow or dividend data being unavailable. The share price is A$2.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Opthea's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Opthea's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:OPT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.09
ASX:OPT Share Price ** ASX (2019-11-18) in AUD A$2.9
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Opthea.

ASX:OPT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:OPT Share Price ÷ EPS (both in AUD)

= 2.9 ÷ -0.09

-32.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Opthea is loss making, we can't compare its value to the Global Biotechs industry average.
  • Opthea is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Opthea's expected growth come at a high price?
Raw Data
ASX:OPT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -32.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
48%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Opthea, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Opthea's assets?
Raw Data
ASX:OPT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.12
ASX:OPT Share Price * ASX (2019-11-18) in AUD A$2.9
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:OPT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:OPT Share Price ÷ Book Value per Share (both in AUD)

= 2.9 ÷ 0.12

23.24x

* Primary Listing of Opthea.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Opthea is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Opthea's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Opthea has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Opthea expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Opthea expected to grow at an attractive rate?
  • Opthea's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Opthea's earnings growth is expected to exceed the Australia market average.
  • Opthea's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:OPT Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:OPT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 48%
ASX:OPT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 39.9%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:OPT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:OPT Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 0 -8 -9 1
2021-06-30 245 135 130 1
2020-06-30 0 -9 -14 1
2019-11-18
ASX:OPT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -24 -21
2019-03-31 0 -20 -19
2018-12-31 0 -15 -17
2018-09-30 0 -18 -17
2018-06-30 0 -20 -17
2018-03-31 0 -17 -16
2017-12-31 0 -15 -15
2017-09-30 0 -10 -11
2017-06-30 0 -6 -6
2017-03-31 0 -5 -7
2016-12-31 0 -5 -7
2016-09-30 0 -4 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Opthea's earnings are expected to grow significantly at over 20% yearly.
  • Opthea's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:OPT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Opthea Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OPT Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30 -0.04 -0.04 -0.04 1.00
2021-06-30 0.52 0.52 0.52 1.00
2020-06-30 -0.05 -0.05 -0.05 1.00
2019-11-18
ASX:OPT Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.09
2019-03-31 -0.09
2018-12-31 -0.08
2018-09-30 -0.08
2018-06-30 -0.08
2018-03-31 -0.08
2017-12-31 -0.08
2017-09-30 -0.06
2017-06-30 -0.04
2017-03-31 -0.04
2016-12-31 -0.05
2016-09-30 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Opthea will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Opthea's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Opthea has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Opthea performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Opthea's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Opthea does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Opthea's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Opthea's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Opthea's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Opthea Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OPT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.24 -20.91 5.20 31.35
2019-03-31 0.21 -18.83 4.77 31.46
2018-12-31 0.19 -16.75 4.34 31.57
2018-09-30 0.17 -16.83 4.50 28.23
2018-06-30 0.15 -16.90 4.67 24.89
2018-03-31 0.12 -16.11 4.86 18.82
2017-12-31 0.09 -15.33 5.05 12.76
2017-09-30 0.08 -10.76 4.88 8.80
2017-06-30 0.07 -6.19 4.71 4.84
2017-03-31 0.08 -6.65 4.76 4.97
2016-12-31 0.08 -7.10 4.81 5.09
2016-09-30 0.21 -6.80 4.43 4.34
2016-06-30 0.34 -6.51 4.06 3.58
2016-03-31 0.48 -5.29 3.75 3.60
2015-12-31 0.61 -4.08 3.44 3.62
2015-09-30 0.60 -4.70 3.41 4.60
2015-06-30 0.58 -5.31 3.38 5.59
2015-03-31 0.69 -5.34 3.18 5.34
2014-12-31 0.80 -5.36 2.98 5.10
2014-09-30 0.79 -4.68 3.17 4.36
2014-06-30 0.79 -4.00 3.36 3.61
2014-03-31 0.70 -3.26 3.55 3.44
2013-12-31 0.60 -2.53 3.74 3.26
2013-09-30 0.62 -3.64 3.88 3.35
2013-06-30 0.64 -4.75 4.01 3.44
2013-03-31 0.62 -5.85 4.01 3.80
2012-12-31 0.60 -6.95 4.00 4.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Opthea has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Opthea has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Opthea improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Opthea's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Opthea has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Opthea's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Opthea's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Opthea is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Opthea's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Opthea's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Opthea has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Opthea Company Filings, last reported 4 months ago.

ASX:OPT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 31.12 0.00 21.53
2019-03-31 31.12 0.00 21.53
2018-12-31 39.74 0.00 40.14
2018-09-30 39.74 0.00 40.14
2018-06-30 38.17 0.00 32.51
2018-03-31 38.17 0.00 32.51
2017-12-31 43.52 0.00 41.94
2017-09-30 43.52 0.00 41.94
2017-06-30 54.49 0.00 51.96
2017-03-31 54.49 0.00 51.96
2016-12-31 13.81 0.00 13.14
2016-09-30 13.81 0.00 13.14
2016-06-30 14.98 0.00 14.66
2016-03-31 14.98 0.00 14.66
2015-12-31 19.00 0.00 17.93
2015-09-30 19.00 0.00 17.93
2015-06-30 21.72 0.00 18.44
2015-03-31 21.72 0.00 18.44
2014-12-31 23.58 0.00 18.99
2014-09-30 23.58 0.00 18.99
2014-06-30 10.48 0.00 7.16
2014-03-31 10.48 0.00 7.16
2013-12-31 13.26 0.00 7.92
2013-09-30 13.26 0.00 7.92
2013-06-30 14.36 0.00 11.00
2013-03-31 14.36 0.00 11.00
2012-12-31 15.62 0.00 12.12
  • Opthea has no debt.
  • Opthea has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Opthea has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Opthea has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Opthea's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Opthea has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Opthea's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Opthea dividends. Estimated to be 0% next year.
If you bought A$2,000 of Opthea shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Opthea's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Opthea's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:OPT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:OPT Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2022-06-30 0.00 1.00
2021-06-30 0.00 2.00
2020-06-30 0.00 2.00
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Opthea has not reported any payouts.
  • Unable to verify if Opthea's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Opthea's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Opthea has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Opthea's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Opthea's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Opthea afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Opthea has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Opthea's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Megan Baldwin
COMPENSATION A$943,171
TENURE AS CEO 5.8 years
CEO Bio

Ms. Megan Baldwin, PhD, MAICD has been the Chief Executive Officer and Managing Director at Opthea Limited since February 24, 2014 and served as its Head of Pre-Clinical Research & Development since January 14, 2008. Ms. Baldwin serves as Chief Executive Officer of Opthea Pty Ltd. Ms. Baldwin joined Circadian in January 2008 and is responsible for research and development of Circadian’s product pipeline. She was employed at Genentech, the world leader in the field of angiogenesis-based therapies for cancer and other diseases. Her experience included several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech’s commercial division and having responsibility for corporate competitive intelligence activities. In this role, she developed extensive knowledge of the angiogenesis and cancer fields. She has a scientific background of more than 10 years, focused on angiogenesis and therapeutic strategies for oncology indications. She serves as a Director of Circadian Technologies Limited. She serves as a Director of Opthea Limited. She holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research.

CEO Compensation
  • Megan's compensation has increased whilst company is loss making.
  • Megan's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Opthea management team in years:

8.2
Average Tenure
  • The average tenure for the Opthea management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Megan Baldwin

TITLE
MD, CEO & Executive Director
COMPENSATION
A$943K
TENURE
5.8 yrs

Mike Tonroe

TITLE
CFO & Company Secretary
COMPENSATION
A$390K
TENURE
5.5 yrs

Annie Lee

TITLE
Finance & Operations Manager

Richard Chadwick

TITLE
Head of Intellectual Property
COMPENSATION
A$220K
TENURE
11.8 yrs

Mike Gerometta

TITLE
Head of CMC Development
COMPENSATION
A$209K
TENURE
10.9 yrs

Ian Leitch

TITLE
Director of Clinical Research
COMPENSATION
A$203K
TENURE
8.2 yrs

James Goding

TITLE
Independent Consultant
Board of Directors Tenure

Average tenure of the Opthea board of directors in years:

4.9
Average Tenure
  • The tenure for the Opthea board of directors is about average.
Board of Directors

Geoffrey Kempler

TITLE
Non-Executive Chairman
COMPENSATION
A$275K
AGE
64
TENURE
4 yrs

Megan Baldwin

TITLE
MD, CEO & Executive Director
COMPENSATION
A$943K

Michael Sistenich

TITLE
Independent Non-Executive Director
COMPENSATION
A$241K
TENURE
4 yrs

Pravin Dugel

TITLE
Member of Clinical Advisory Board
AGE
55
TENURE
4.9 yrs

Mark Gillies

TITLE
Member of Clinical Advisory Board
TENURE
4.9 yrs

Peter Campochiaro

TITLE
Member of Clinical Advisory Board
TENURE
4.9 yrs

Kameran Lashkari

TITLE
Member of Clinical Advisory Board
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
12. Sep 19 Buy Ki Corporation Limited Company 07. Sep 19 07. Sep 19 2,915,090 A$3.23 A$9,415,263
14. Aug 19 Buy Ki Corporation Limited Company 19. Jan 17 07. Aug 19 13,360,137 A$0.75 A$10,033,318
29. Oct 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 22. Oct 19 24. Oct 19 -30,760 A$3.59 A$-110,311
29. Oct 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 22. Oct 19 24. Oct 19 355,085 A$3.74 A$1,327,828
24. Oct 19 Sell Credit Suisse, Investment Banking and Securities Investments Company 09. Aug 19 21. Oct 19 -7,483,323 A$3.12 A$-23,360,448
24. Oct 19 Buy Credit Suisse, Investment Banking and Securities Investments Company 07. Aug 19 21. Oct 19 6,465,457 A$2.91 A$18,844,040
09. Oct 19 Buy Merrill Lynch & Co. Inc., Banking Investments Company 04. Oct 19 04. Oct 19 224,978 A$3.39 A$760,454
08. Oct 19 Sell Merrill Lynch & Co. Inc., Banking Investments Company 27. Aug 19 01. Oct 19 -1,535,618 A$2.67 A$-4,094,667
08. Oct 19 Buy Merrill Lynch & Co. Inc., Banking Investments Company 26. Aug 19 01. Oct 19 10,660,460 A$3.00 A$31,997,278
07. Oct 19 Sell BVF Partners LP Company 07. Oct 19 07. Oct 19 -13,105,918 A$3.10 A$-40,628,337
29. Aug 19 Sell BVF Partners LP Company 20. Aug 19 27. Aug 19 -10,500,000 A$2.70 A$-28,279,138
27. Aug 19 Buy Regal Funds Management Pty Limited Company 23. Aug 19 23. Aug 19 3,213,374 A$2.70 A$8,676,106
18. Aug 19 Sell BVF Partners LP Company 05. Jun 19 05. Jun 19 -742,678 A$0.66 A$-490,167
18. Aug 19 Buy BVF Partners LP Company 05. Jun 19 05. Jun 19 742,678 A$0.66 A$490,167
18. Aug 19 Sell BVF Partners LP Company 05. Jun 19 15. Aug 19 -14,100,000 A$2.86 A$-38,045,540
15. Aug 19 Buy Regal Funds Management Pty Limited Company 20. Jun 19 13. Aug 19 4,287,070 A$2.60 A$9,763,902
14. Aug 19 Sell Baker Bros. Advisors LP Company 18. Sep 18 21. Nov 18 -116,714 A$0.56 A$-65,093
14. Aug 19 Buy Baker Bros. Advisors LP Company 07. Aug 19 12. Aug 19 5,868,932 A$1.92 A$11,249,660
04. Jun 19 Sell Regal Funds Management Pty Limited Company 28. Nov 18 28. Nov 18 -3,000,000 A$0.57 A$-1,709,998
04. Jun 19 Buy Regal Funds Management Pty Limited Company 30. May 18 29. May 19 4,336,717 A$0.60 A$2,580,200
04. Apr 19 Sell Megan Baldwin Individual 04. Apr 19 04. Apr 19 -667,000 A$0.66 A$-440,220
X
Management checks
We assess Opthea's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Opthea has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Opthea Limited (ASX:OPT) Excessively Paying Its CEO?

See our latest analysis for Opthea How Does Megan Baldwin's Compensation Compare With Similar Sized Companies? … We examined companies with market caps from AU$295m to AU$1.2b, and discovered that the median CEO total compensation of that group was AU$973k. … Most shareholders would probably be pleased with Opthea Limited for providing a total return of 333% over three years.

Simply Wall St -

Does The Opthea Limited (ASX:OPT) Share Price Tend To Follow The Market?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … What this means for you: Since Opthea is not heavily influenced by market moves, its share price is probably far more dependend on company specific developments.

Simply Wall St -

Breakeven On The Horizon For Opthea Limited (ASX:OPT)

Many investors are wondering the rate at which OPT will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for OPT, its year of breakeven and its implied growth rate. … So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment. … For a more comprehensive look at OPT, take a look at OPT’s company page on Simply Wall St.

Simply Wall St -

Need To Know: Opthea Limited (ASX:OPT) Insiders Have Been Selling Shares

So shareholders might well want to know whether insiders have been buying or selling shares in Opthea Limited (ASX:OPT). … See our latest analysis for Opthea Opthea Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the MD, CEO & Executive Director, Megan Baldwin, sold AU$440k worth of shares at a price of AU$0.66 per share. … While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign.

Simply Wall St -

Is Opthea Limited's (ASX:OPT) CEO Being Overpaid?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … Check out our latest analysis for Opthea … How Does Megan Baldwin's Compensation Compare With Similar Sized Companies?

Simply Wall St -

What Kind Of Shareholders Own Opthea Limited (ASX:OPT)?

Every investor in Opthea Limited (ASX:OPT) should be aware of the most powerful shareholder groups. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Companies that have been privatized tend to have low insider ownership.

Simply Wall St -

Loss-Making Opthea Limited (ASX:OPT) Expected To Breakeven

With the latest financial year loss of -AU$16.9m and a trailing-twelve month of -AU$16.8m, the AU$181m market-cap alleviates its loss by moving closer towards its target of breakeven. … I’ve put together a brief outline of industry analyst expectations for OPT, its year of breakeven and its implied growth rate … OPT is bordering on breakeven, according to the 2 Biotechs analysts.

Simply Wall St -

Opthea Limited (ASX:OPT): The Best Of Both Worlds

I've been keeping an eye on Opthea Limited (ASX:OPT) because I'm attracted to its fundamentals. … Looking at the company as a whole, as a potential stock investment, I believe OPT has a lot to offer. … is a company with

Simply Wall St -

What You Must Know About Opthea Limited's (ASX:OPT) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is OPT right in choosing financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Is Opthea Limited's (ASX:OPT) CEO Pay Justified?

Megan Baldwin became the CEO of Opthea Limited (ASX:OPT) in 2014. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Megan Baldwin's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Company Info

Description

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase Ib/IIa clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Details
Name: Opthea Limited
OPT
Exchange: ASX
Founded:
A$720,834,736
250,289,839
Website: http://www.opthea.com
Address: Opthea Limited
650 Chapel Street,
Suite 0403,
South Yarra,
Victoria, 3141,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX OPT Ordinary Shares Australian Securities Exchange AU AUD 02. Jan 1992
DB UKJ Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
CHIA OPT Ordinary Shares Chi-X Australia AU AUD 02. Jan 1992
OTCPK CKDX.Y SPONSORED ADR Pink Sheets LLC US USD 07. Jun 2011
Number of employees
Current staff
Staff numbers
0
Opthea employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:31
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/10/17
Last earnings filing: 2019/08/08
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.